

Annual Report

FOR THE YEAR ENDED
30 JUNE 2023



me | today®



Contents

CHAIR & CEO REPORT	3
DIRECTORS' PROFILES	8
FINANCIAL STATEMENTS	
Consolidated Statement of Profit and Loss and Other Comprehensive Income	13
Consolidated Statement of Changes in Equity	14
Consolidated Statement of Financial Position	15
Consolidated Statement of Cash Flows	16
Notes to the Consolidated Financial Statements	17
INDEPENDENT AUDITOR'S REPORT	48
CORPORATE GOVERNANCE STATEMENT	53
SHAREHOLDER & STATUTORY INFORMATION	58



Chair & CEO Report



Dear Shareholder

Me Today's financial results for the year ended 30 June 2023 includes twelve months trading of the King Honey business together with the Me Today brand and the agency business the Good Brand Company.

The Group recorded net revenue of \$7.88m and a loss after tax of \$12.97m. The operating EBITDA loss was \$5.15m after adding back non-recurring and non-cash items of \$7.82m.*

Gross revenue for the Group before the costs of marketing services provided by a customer was \$9.20m. This was split between the King Honey business at \$5.82m, Me Today branded sales of \$2.78m and agency services revenue at \$0.60m.

The trading environment for the business continued to be challenging given the performance of the largest customer trading in the Chinese market. The 2023 Manuka Honey season was also challenging as a result of the significant weather events during the year. The honey harvest both in volume and quality was well down on average which resulted in a financial loss on the harvest this year.

Given the large holding of Manuka honey, the Group decided to further reduce the size of its beekeeping operation. This reduction is in addition to the changes announced last year and takes total hive numbers to approximately 1,600 hives operating out of Turangi.

Together with the reduction in beekeeping, the Group has continued to reduce expenditure across the other parts of its business. The Group continues to create sales opportunities across its three core brands of Me Today, BEE+ and SuperLife. The sales activity comes from new customers and repeat business with existing customers.

The Group will continue to review its cost base and make necessary adjustments as required. It is also considering funding alternatives to lower a part of its term debt which may include the sale of assets or raising new capital.

As part of the year end audit process the group considered the carrying value of its intangible assets given the continuing challenging market for selling Manuka honey. The result is the directors have decided to make a further impairment by writing down the value of the intangible assets associated with the King Honey asset by an additional \$2.36m.

An overview of the activity of the Group for the year is summarized as follows.

Me Today

The strategy in respect to the Me Today brand continues to be the investment into the brand locally in New Zealand and Internationally.

In New Zealand the brand has a strong national presence in pharmacy and grocery stores with Me Today stocked in all Countdown stores and partnerships with major pharmacy banners Chemist Warehouse and Bargain Chemist. Me Today also has a good presence in selected Unichem and Life Pharmacy stores as well as a number of good independents throughout New Zealand.

The international strategy remains focused on the following core markets, US, Japan, Ireland, the UAE and Australia.

- In Ireland the brand is listed with Chemist Warehouse and Tesco and is also stocked in selected pharmacy stores around the country.
- In the US the positioning of the brand is in partnership with major Online platforms. The USA business of Me Today has a logistics hub based out of Arkansas with orders distributed from this warehouse nationwide in the USA. The brand is also in discussion with bricks and mortar retailers, and it is fulfilling orders

through a west coast broker.

- Repeat orders continue in Japan and the UAE and we continue to develop the brand and partnerships in these markets.
- In Australia we have an Online presence, and we are in discussions with two large retailers in respect to a wider listing.

Across all markets Online sales are proving to be a good way of building the brand footprint and creating interest in the brand to enable access to big box retailers.

Together with the core market strategy the brand continues to invest in new product development.

Launched in the 2023 financial year have been the following new products.

- 3 UMF rated Me Today Manuka Honey products
- 4 Me Today Manuka Honey Lozenges
- 9 new Me Today supplements
- 4 Me Today Manuka Active skincare products

Projects under development for launch in the remainder of the 2023 calendar year include a Me Today Super Honey which will see a range of infused

* Refer to note 7. Segment Information

honey products launched. The initial launch will take place in New Zealand with opportunities in international markets currently being considered.

From a product development perspective we will continue to see development across the 3 key product platforms being: Manuka Honey, Supplements and skincare.

The Good Brand Company

The Good Brand Company represents the groups brands being: Me Today and SuperLife whilst also representing four other agency brands. The group has invested in people growing the expertise and skillset of its staff to support the growth of The Good Brand Company's stable of brands and has capacity to bring on new agency brands with the right fit.

The King Honey business

King Honey operates a fully integrated Hive to table Manuka honey business. It has production, storage and a bottling facility in Taupo and operates a beekeeping operation based out of Turangi.

As discussed above the beekeeping operations have been further reduced through the closing of the Wairarapa unit leaving a 1,600-hive operation managed from Turangi. King Honey has a large quantity of beekeeping equipment which means that it has the ability to increase hive numbers as demand requires.

King Honey manages the production of the BEE+ and SuperLife brands as well as contract packing on behalf of a number of other labels.

BEE +

The group continues to have a good relationship with the Bee+ Brand through Access Corporate Group (ACG) and its brand management division Access Brand Management (ABM). ABM and the Me Today Group jointly own the Bee+ Mānuka honey brand.

In conjunction with ABM, Me Today has developed new product offerings with the BEE+ brand which it has produced and delivered during the FY23 year. ABM are committed to the development of the brand and Me Today are continuing to support ABM in respect to the growth of the brand.

SuperLife

SuperLife provides the Group with a Mānuka honey brand that competes in different parts of the market to both Me Today and BEE+. It has customer and distributor relationships across a number of international markets. The opportunities within these markets continue to change as the sell-through rate of products is established.

The largest opportunity for SuperLife continues to be the relationship with a US grocery chain. Sell through has been positive for FY23 with sales into the US for SuperLife more than NZD \$1m for the 2023 financial year. Range extension and new product development opportunities exist with this retailer.

Outside NZ and the USA, the focus markets for SuperLife are Germany, Romania and the UAE with sales and reorders into these markets over the past six months.

The Group's outlook for the year ahead remains challenging. However, the Group is confident that it has the right strategies in place to reduce costs and improve sales across its brands. The Group will continue to review its options for funding and will make further announcements as appropriate.



The board would like to thank shareholders for their support over the past year. The board would also like to thank our employees for their hard work during the 2023 financial year.

A stylized, handwritten signature in brown ink, consisting of a large 'G' and 'B' intertwined.

Grant Baker
Chairman

A stylized, handwritten signature in brown ink, consisting of a large 'M' and 'K' intertwined.

Michael Kerr
CEO





SuperLife™
Wildflower honey
with Mānuka

100% natural
New Zealand honey

30
MGO

NET WT
250g

Directors' Profiles





Grant Baker

NON-EXECUTIVE CHAIRMAN

Appointed to the Board, March 2020

Grant Baker has wide experience at a senior level in both public and private New Zealand companies. He is currently the chairman of Turners Automotive Group, a position he has held for more than 10 years. He was a cofounder of The Business Bakery and has a number of successes under his belt, including being chairman of both 42 Below vodka and Trilogy International. 42 Below was sold to Bacardi in 2006, and Trilogy was sold to CITIC Group. Grant is also a cancer survivor and has a strong interest in the health and wellbeing sector. Until recently he was the chairman of The Gut Cancer Foundation, a position he held for more than 10 years.

Grant is not considered to be an independent director under the NZX Listing Rules as MTL Securities Limited, a company in which he is a director, is a substantial product holder of Me Today. Also, interests associated with Grant have an ownership interest in MTL Securities Limited.



Michael Kerr

CHIEF EXECUTIVE OFFICER / EXECUTIVE DIRECTOR

Appointed to the Board, March 2020

Michael holds a Bachelor of Commerce degree, majoring in marketing and management, from the University of Auckland. Michael has worked in sales and marketing roles for several local and multinational businesses. More recently he was responsible for establishing the Swisse brand in New Zealand across multiple retail channels, and was the general manager of the skincare brand, Trilogy. Michael's career spans 20 years, in which time he has developed a wealth of knowledge both locally and internationally of how to create and grow brands in the Health and Wellness space.

Michael is not considered to be an independent director under the NZX Listing Rules as he is the Chief Executive Officer and a director of MTL Securities Limited, a substantial product holder of Me Today. Interests associated with Michael have an ownership interest in MTL Securities Limited.



Stephen Sinclair

EXECUTIVE DIRECTOR

Appointed to the Board, March 2020

Stephen is a Chartered Accountant, and spent the early part of his career with PriceWaterhouseCoopers. In 1999 he started working with Grant Baker and since then has been involved with numerous successful startups, including 42 Below, Ecoya and Trilogy, and was involved in the recapitalisation of Dorchester Pacific which is now the Turners Automotive Group.

Stephen is not considered to be an independent director under the NZX Listing Rules as MTL Securities Limited, a company in which he is a director, is a substantial product holder of Me Today. Interests associated with Stephen have an ownership interest in MTL Securities Limited. Stephen also provides consulting services to Me Today.

Hannah Barrett

INDEPENDENT DIRECTOR

Appointed to the board, March 2020

Hannah has a Bachelor of Commerce degree, majoring in commercial law and accounting, from Victoria University and is a qualified Chartered Accountant. Hannah spent three years working at PricewaterhouseCoopers in the Financial Advisory team working on assignments for global companies as well as New Zealand based businesses and individuals. Hannah also runs her own business specialising in digital consulting and marketing. Hannah supports a number of charities and is an ambassador for Sweet Louise.



Roger Gower

INDEPENDENT DIRECTOR

Appointed to the Board, July 2008

Roger has wide experience as a company executive, director and Chairman in both public and private companies. He is currently Chairman of PrimePort Timaru Limited and New Zealand Food Innovation Auckland Limited (the Food Bowl). Roger is the Chief Executive of New Zealand's Best Food & Beverage Limited, a company affiliated with Douglas Pharmaceuticals that has developed wellbeing products targeting the mother & baby and aged care sectors under the Douglas Nutrition brand. Roger was Chairman at Charlie's juice company, which listed in 2005 and prior to that had a corporate career in logistics and transportation. Roger has a BCom from the University of Auckland, an MBA from Massey University and an MPhil from the University of Cambridge.



Antony Vriens

INDEPENDENT DIRECTOR

Appointed to the board, March 2020

Antony is a seasoned executive with a career in health and financial services corporations across New Zealand, Australia and Asia. He is currently an Independent Director of the Turners Automotive Group, and is the Chairman of DPL Insurance Limited (Turners' insurance subsidiary). Antony is a medical doctor by background and brings a strong interest in wellness and nutrition, which is supported by his medical training. Antony is also currently involved in new health technology initiatives to support lifestyle change in the Asia region. In addition to his medical degree, Antony holds an MBA from the University of Auckland, with a background in international business and innovation.



Richard Pearson

NON-EXECUTIVE DIRECTOR

Appointed to the board, November 2021

Richard has been Chairman of Wellington Electricity Distribution Network Limited and its subsidiary companies since the organisation's establishment in 2008. He was also appointed Chairman of Enviro (NZ) Limited in 2013. Prior to his current positions, Richard worked for Hutchison Whampoa Group (now known as CK Hutchison Holdings) from 1975 to 2007, holding various senior roles in Hutchison Port Holdings Group, including Managing Director – Europe Division from 2005 to 2007, President of ECT Rotterdam from 2002 to 2004, as well as Managing Director of Hongkong International Terminals Ltd from 1996 to 1998. Richard holds a Bachelor's degree in Commerce. Richard is not considered to be an independent director under the NZX listing rules due to an association with the trustees of the TW Jarvis (No. 1) Trust, the company's second largest shareholder.





Mānuka
honey

UMF 5+ | MGO 83+
NET WT 125g e

me today

Financial Statements

FOR THE YEAR ENDED 30 JUNE 2023



Consolidated Statement of Profit and Loss and Other Comprehensive Income

FOR THE YEAR ENDED 30 JUNE 2023

	Note	30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Revenue before marketing services provided by a customer		9,201	8,811
Less marketing services provided by customers		(1,318)	(538)
Revenue	5	7,883	8,273
Changes in inventories of finished goods and work in progress		(4,767)	(5,132)
Selling and marketing expenses		(2,968)	(3,729)
Distribution expenses		(861)	(610)
Administrative and other operating expenses		(4,881)	(5,489)
Amortisation of customer relationship asset	19	(1,083)	(1,084)
Finance income		4	13
Finance expenses	6	(594)	(641)
Acquisition related costs		(115)	(368)
Operating loss before tax, fair value adjustments, restructuring and impairment costs	6	(7,382)	(8,767)
Fair value loss on harvested honey	14	(2,223)	(1,724)
Fair value loss on biological assets	15	(544)	(720)
Restructuring costs		(337)	(494)
Write down of assets held for sale	13	(128)	(543)
Impairment of goodwill	19.1	-	(9,120)
Impairment of customer relationship asset	19.1	(2,360)	(780)
Loss before income tax		(12,974)	(22,148)
Income tax (expense)/benefit	8	-	2,604
Loss for the period attributable to owners of the company		(12,974)	(19,544)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange differences on translation of foreign operations		(69)	-
Total comprehensive loss for the period attributable to owners of the company		(13,043)	(19,544)
Earnings (loss) per share:			
Basic and diluted loss per share (NZ\$)	9	(0.009)	(0.029)

The accompanying notes form part of these consolidated financial statements and should be read in conjunction with them.

Consolidated Statement of Changes in Equity

FOR THE YEAR ENDED 30 JUNE 2023

	Note	Share capital NZ\$000	Share based payments reserve NZ\$000	Accumulated losses NZ\$000	Foreign currency translation reserve NZ\$000	Total equity NZ\$000
At 1 April 2021		13,669	110	(7,887)	-	5,892
Total comprehensive income						
Loss attributable to owners of the company		-	-	(19,544)	-	(19,544)
Transactions with owners						
Shares issued during the period	22	28,733	(177)	-	-	28,556
Less: share issue costs		(975)	-	-	-	(975)
Shares issued on acquisition of subsidiaries		10,000	-	-	-	10,000
Share options issued	24	-	30	-	-	30
Share options expired	23	-	(26)	26	-	-
Other share based payments	23	-	140	-	-	140
At 30 June 2022		51,427	77	(27,405)	-	24,099
Total comprehensive income						
Loss attributable to owners of the company		-	-	(12,974)	-	(12,974)
Exchange differences on translation foreign operations		-	-	-	(69)	(69)
Transactions with owners						
Shares issued during the period	22	1,026	(159)	-	-	867
Less: share issue costs		(72)	-	-	-	(72)
Share options issued	23	-	-	-	-	-
Share options expired	23	-	(13)	-	-	(13)
Other share based payments	23	-	95	-	-	95
At 30 June 2023		52,381	-	(40,379)	(69)	11,933

The accompanying notes form part of these consolidated financial statements and should be read in conjunction with them.

Consolidated Statement of Financial Position

AS AT 30 JUNE 2023

	Note	2023 NZ\$000	2022 NZ\$000
ASSETS			
Current assets			
Cash and cash equivalents	10	913	5,370
Trade and other receivables	11	2,443	1,199
Inventory	12	14,759	16,793
Biological work in progress	14	160	698
Taxation receivable		11	35
		18,286	24,095
Assets classified as held for sale	13	93	1,063
Total current assets		18,379	25,158
Non-current assets			
Biological assets	15	752	1,598
Property, plant and equipment	16	2,958	3,788
Right-of-use asset	17.1	770	1,387
Customer relationship asset	19	3,993	7,436
Intangible assets	19	98	89
Total non-current assets		8,571	14,298
Total assets		26,950	39,456
LIABILITIES			
Current liabilities			
Trade and other payables	20	1,777	1,766
Lease liabilities	17.2	334	316
Borrowings	21	7,248	942
Total current liabilities		9,359	3,024
Non-current liabilities			
Lease liabilities	17.2	472	1,041
Borrowings	21	5,186	11,292
Total non-current liabilities		5,658	12,333
Total liabilities		15,017	15,357
Net assets		11,933	24,099
EQUITY			
Share capital	22	52,381	51,427
Share based payments reserve	23	-	77
Accumulated losses		(40,379)	(27,405)
Foreign currency translation reserve		(69)	-
Total equity		11,933	24,099

These financial statements were approved by the Board on 29 August 2023.

Signed on behalf of the Board by:



Grant Baker



Michael Kerr

Consolidated Statement of Cash Flows

FOR THE YEAR ENDED 30 JUNE 2023

	Note	30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Cash flows from operating activities			
Receipts from customers		7,949	8,270
Payments to suppliers and employees		(13,534)	(19,998)
Interest received		4	13
Income tax paid		26	(11)
Net cash used in operating activities	25	(5,555)	(11,726)
Cash flows from investing activities			
Proceeds from short term deposits		-	3,804
Acquisition of subsidiaries		-	(20,791)
Acquisition related costs		(115)	(368)
Payments for property, plant and equipment		(35)	(327)
Proceeds from sale of property, plant and equipment		1,410	97
Payments for intangibles		(11)	126
Net cash used in investing activities		1,249	(17,459)
Cash flows from financing activities			
Proceeds from issue of share capital		739	27,983
Share capital issue costs		(72)	(474)
Proceeds from bank borrowings	26	-	8,500
Repayment of principal on borrowings	26	-	(1,466)
Interest paid on borrowings	26	(377)	(379)
Payment of lease liabilities	26	(355)	(742)
Interest paid on lease liabilities	26	(17)	(62)
Net cash flows from financing activities		(82)	33,360
Net (decrease)/increase in cash and cash equivalents		(4,388)	4,175
Cash and cash equivalents at the beginning of the period		5,370	1,195
Effect of foreign exchange rates		(69)	-
Cash and cash equivalents at the end of the period	10	913	5,370

The accompanying notes form part of these consolidated financial statements and should be read in conjunction with them.

Notes to the Consolidated Financial Statements

FOR THE YEAR ENDED 30 JUNE 2023

1. GENERAL INFORMATION

Me Today Limited ('the Company') is a limited liability company incorporated and domiciled in New Zealand.

These financial statements are for Me Today Limited and its subsidiaries (together 'the Group'). Details of subsidiary companies and their principal activities are set out in note 27.

The Group:

- produces, sells, and markets health and wellbeing products or acts as an agent on behalf of other health and wellbeing suppliers; and
- produces premium manuka honey.

In 2022 the Company changed its annual reporting date to 30 June and, as a result of the change, the comparative amounts are for the 15 months ended 30 June 2022, unless otherwise stated.

2. BASIS OF PREPARATION

2.1. Basis of measurement

The consolidated financial statements have been prepared on a historical cost basis, except for biological assets which are measured at fair value less cost to sell. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

The consolidated financial statements are presented in New Zealand dollars which is the Company's functional and Group's presentation currency, rounded to the nearest thousand dollars unless otherwise stated.

2.2. Statement of compliance and reporting framework

The consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand ('NZ GAAP'). The Group is a for-profit entity for the purposes of complying with NZ GAAP. The consolidated financial statements comply with New Zealand equivalents to International Financial Reporting Standards ('NZ IFRS') and International Financial Reporting Standards ('IFRS').

The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013. These consolidated financial statements have been prepared in accordance with the requirements of the Financial Markets Conduct Act 2013 and the NZX Main Board Listing Rules.

3. SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies adopted are set out below. There have been no changes in accounting policies since the previous reporting date unless otherwise stated.

3.1. Principles of consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and
- has the ability to use its power to affect its returns.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

3.2. Revenue recognition

The Group recognises revenue from the following major sources:

- sale of goods; and
- agency services.

Revenue is measured based on the consideration to which the Group expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties, such as goods and service tax and customs duties.

3.2.1 Sale of goods

The Group sells goods such as health and wellbeing products, and honey products. The Group considers the performance obligation is satisfied when control of the goods has transferred, being when the goods have been delivered to the customer. Revenue derived from the sale of goods is recognised at the point in time the performance obligation is satisfied. Marketing payments paid to a customer for the purchase of health and wellbeing products, are treated as a reduction in revenue.

3.2.2 Agency services

For revenues derived from agency services, where the Group acts as a sales agent for other health and wellness brands, the Group considers its performance obligations are satisfied over time, on the basis that agency services are provided and consumed by the customer on a simultaneous basis, and so will recognise the related revenue as the performance obligation is satisfied. Revenue is measured on an output method basis.

3.3. Income Tax

Income tax expense comprises both current and deferred tax.

3.3.1 Current tax

The tax currently payable is based on taxable profit for the period. Taxable profit differs from 'profit before tax' as reported in the statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other periods and items that are never taxable or deductible. The Group's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

3.3.2 Deferred tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences except for the initial recognition of goodwill and the initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting or taxable profit. Deferred tax assets are recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects,

at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

3.4. Goods and services tax

Revenue, expenses, assets and liabilities are recognised net of the amount of goods and services tax (GST) except:

- where the amount of GST incurred is not recovered from the taxation authority, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense; or
- for receivables and payables, which are recognised inclusive of GST.

The net amount of GST recoverable or payable to the taxation authority is included as part of receivables or payables.

3.5. Inventories

Inventories are stated at the lower of cost and net realisable value. Costs of inventories are determined on a first-in-first-out basis. Net realisable value represents the estimated selling price for inventories less estimated costs of completion and costs necessary to make the sale.

The deemed cost for the Group's agricultural produce (honey) inventory is fair value at harvest less estimated point-of-sale costs. Fair value is determined by reference to selling prices for honey. Point-of-sale costs include all costs that would be necessary to sell the assets.

3.6. Biological assets

Biological assets consist of bees (including queens).

Biological assets are measured at fair value less point-of-sale costs, with any change therein recognised in the profit or loss. Point-of-sale costs include all costs that would be necessary to sell the assets. The fair value of biological assets is assessed on an annual basis post-harvest, which involves reviewing the number of operational hives in use and referencing market prices for hives.

3.7. Biological work in progress

Biological work in progress consists of unharvested honey.

Biological assets are measured at fair value less point-of-sale costs, with any change therein recognised in the profit or loss. Point-of-sale costs include all costs that would be necessary to sell the assets.

The growth in the biological work in progress in the

period from harvest to 30 June cannot be reliably measured at fair value due to the variables in hive growth and honey production between harvest and reporting date. Therefore, as required under NZ IAS 41: Agriculture, the cost of agricultural activity (beekeeping costs) in the period to 30 June has been capitalised as biological work in progress to account for this growth.

Agricultural produce (honey) from biological assets is transferred to inventory at fair value, by reference to market prices for honey less estimated point-of-sale costs, at the date of harvest. The biological work in progress is transferred to inventory as part of this fair value recognition at each harvest, which occurs at least annually. A fair value loss on honey harvest was recognised in the loss for the period (note 15).

3.8. Leasing

The Group assess whether a contract is or contains a lease, at inception of the contract. The Group recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and lease of low value assets. For these leases, the Group recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefit from the leased assets are consumed.

The lease liability is initially measured at the present value of the future lease payments, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate. The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option, with a corresponding adjustment made to the carrying value of the right-of-use asset.

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement date and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated over the shorter period of lease term and the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The Group applies NZ IAS 36: Impairment of Assets to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in the 'property, plant and equipment' policy.

3.9. Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values, over their useful lives using the diminishing value method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

The following depreciation rates are used in the calculation:

Plant, vehicles and equipment	6% – 67%
Office equipment and furniture	10% – 50%
Leasehold improvements	6% – 25%

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

3.10. Assets held for sale

Biological assets held for sale are measured at fair value less costs to sell. Other non-current assets classified as held for sale are measured at the lower of carrying amount and fair value less costs to sell. Non-current assets are classified as held for sale if their carrying amount will be recovered through a sale transaction rather than through continuing use. This condition is regarded as met only when the sale is highly probable and the asset is available for immediate sale in its present condition. The Group must be committed to the sale which should be expected to qualify for recognition as a completed sale within one year from the date of classification.

3.11. Intangible assets

Acquired intangible assets with finite useful lives are carried at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite

useful lives that are acquired separately are carried at cost less accumulated impairment losses.

The following amortisation rates are used in the calculation:

Customer relationship	12.5%
Website	50%
Trademarks & domains	indefinite useful life

3.12. Financial instruments

Financial assets and financial liabilities are recognised in the Consolidated Statement of Financial Position when the Group becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition.

3.13. Financial assets

Financial assets are measured at amortised cost on the basis that the Group's business model for managing financial assets and the contractual cash flow characteristics of the financial assets. The Group classifies its financial assets as at amortised cost only if both of the following criteria are met:

- the asset is held within a business model whose objective is to collect the contractual cash flows: and
- the contractual terms give rise to cash flows that are solely payments of principal and interest.

Financial assets at amortised costs

The Group holds receivables with the objective to collect the contractual cash flows, the cash flows are solely payments of principal and interest, and therefore measures them subsequently at amortised cost using the effective interest method, less impairment provisions.

The Group's financial assets at amortised cost include cash and cash equivalents, short term deposits and trade receivables. Cash and cash equivalents include cash in hand and deposits held at call with banks.

Impairment of financial assets at amortised cost

The Group recognises a loss allowance for expected credit losses on trade receivables. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument.

The Group recognises lifetime expected credit losses for trade receivables. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate.

3.14. Financial liabilities

Financial liabilities (including trade, other payables and borrowings) are subsequently measured at amortised cost using the effective interest method. The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the net carrying amount on initial recognition.

3.15. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors.

3.16. Foreign currency translation

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions.

At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences on monetary items are recognised in the profit or loss in the period in which they arise.

For the purpose of presenting consolidated financial statements, the assets and liabilities of the Group's foreign operations are translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the date of

transactions are used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in a foreign exchange translation reserve.

3.17. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction, net of tax, from the proceeds.

3.18. Share based payment transactions

For equity-settled share-based payments where the goods or services acquired from non-employees can be measured reliably, then the goods or services are measured directly at their fair value. If goods or services cannot be measured reliably, or for transactions with employees, the goods or services are measured indirectly, i.e. with reference to the fair value of equity instruments granted.

The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity.

At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share-based payments reserve.

3.19. Borrowing costs

Borrowing costs are capitalised, net of interest received on cash drawn down yet to be expended when they are directly attributable to the acquisition, contribution or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale.

3.20. Application of new and revised International Financial Reporting Standards

The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective. Early adoption of these new standards, interpretations or amendments would not have had a material impact on the financial result or financial position of the Group.

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

In the application of the Group's accounting policies, which are described in note 3, the directors of the Group are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Below are the critical accounting judgements.

4.1. Going concern

The consolidated financial statements have been prepared on a going concern basis, which assumes that the Group has the intention and ability to continue its operations for the foreseeable future.

The Group incurred an after-tax loss of \$12.97 million in the year to 30 June 2023 (15 month period to 30 June 2022: \$19.54 million loss). The Group's net cash outflows from operating activities during the year was \$5.56 million (15 months to 30 June 2022: \$11.73 million net cash outflow).

At the reporting date the Group had cash of \$0.9 million (2022: \$5.4 million), working capital of \$9.0 million (2022: \$22.1 million) and net assets of \$11.9 million (2022: \$24.1 million).

As at 30 June 2023, the Group had bank loans of \$7.0 million (2022: \$7.0 million), and \$5.4 million was payable to the previous owners of King Honey under a subordinated note (2022: \$5.2 million) which, as at the reporting date, was due for payment to the previous owners of King Honey in June 2024.

The Group's banker, Bank of New Zealand, has confirmed that it will keep the Group's existing bank facilities in place (refer note 21) subject to further review no later than 31 August 2024 in conjunction with the FY24 audited financial statements and FY25 budget. The facilities include an unused overdraft of \$5 million. The facilities will remain on an interest only basis until 31 August 2024. The requirement for an amortisation programme will be considered at that time in conjunction with the FY25 budget. The bank also confirmed the continued suspension of earnings-related covenants until 31 August 2024.

On 28 August 2023, the Jarvis Trust has agreed to extend the repayment date of the subordinated note for nine months to 31 March 2025 (refer note 21). A

condition of this extension is that the Group cannot increase its indebtedness to the BNZ above \$9.5 million without the consent of the Jarvis Trust.

The Directors are satisfied that based on their review of the Group's current financial forecasts, confirmation from the Group's banker of the existing facilities, and the extension agreement with Jarvis Trust, that, during the 12 months after the date of signing these consolidated financial statements, there will be adequate cash flows available to meet the financial obligations of the Group as they arise. The Directors acknowledge that whilst the Group continues to build commercial relationships with new and existing customers future looking forecasts are inherently uncertain. The Directors consider the overdraft facility available to the Group (as modified by the Jarvis Trust condition) provide it with sufficient headroom should it be required if sales or cost forecasts are not achieved.

The considered view of the Board is that, after making due enquiries and considering relevant factors, there is a reasonable expectation that the Group will have access to adequate resources and commitments from its borrowers, that will enable it to meet its financial obligations for the foreseeable future.

For this reason, the Board considers the adoption of the going concern basis in preparing the consolidated financial statements for the year ended 30 June 2023 to be appropriate. The Board has reached this conclusion having regard to circumstances which it considers likely to affect the Group during the period of at least one year from the date of approval of these consolidated financial statements, and to circumstances which it considers will occur after that date which will affect the validity of the going concern basis.

4.2. Fair value of inventory at harvest

The deemed cost for the Group's agricultural produce (honey) inventory is fair value at harvest less estimated point-of-sale costs. Fair value is determined by reference to market prices for honey. Judgement is required to determine the market price of the honey at harvest based upon each drum's tested chemical markers (refer note 14).

4.3. Impairment of customer relationship asset

The cash-generating unit to which the customer relationship asset has been allocated is tested for impairment when there is an indication that the unit may be impaired. The Board has undertaken value in use impairment testing and reviewed sensitivity analysis relating to the carrying value of the customer relationship asset. Judgement is required in determining the extent to which there has been an impairment in value (refer note 19.1).

4.4. Inventory net realisable value

Inventories are carried at the lower of cost and net realisable value. Management has identified that based on near term forecast demand there is currently excess inventory held and therefore there may be issues in achieving the carrying value of this inventory. They have estimated this excess quantity by grade of honey and have considered its net realisable value by reference to the likely manner in which it will be used. There is judgement involved in these estimates (refer note 12).

4.5. Fair value of biological assets

Biological assets are measured at fair value less point-of-sale costs. The fair value of biological assets is assessed on an annual basis post-harvest, which involves reviewing the number of operational hives in use and referencing market prices for hives. Judgement is required to determine the fair value of hives (refer note 15).

4.6. Fair value of biological work in progress

Biological assets are measured at fair value less point-of-sale costs. The growth in the biological work in progress in the period from harvest to 30 June cannot be reliably measured at fair value due to the variables in hive growth and honey production between harvest and the reporting date. Therefore, as required under NZ IAS 41: Agriculture, the cost of agricultural activity (beekeeping costs) in the period to 30 June has been capitalised as biological work in progress to account for this growth (refer note 14).

4.7. Deferred tax

Judgement is exercised in determining the timing and extent of recognition of the benefit of tax losses. The benefit of tax losses can be recognised as an asset if its recovery is 'probable' (more likely than not). In the absence of any track record of profitability, convincing evidence is needed of how the losses will be recovered in the future, before any deferred tax asset is recognised. At 30 June 2023 the Group has recognised the benefit in respect of the tax losses generated to the extent they offset a deferred tax liability (refer note 8).



4.8. Accounting for leases

Judgement is required in determining whether it is reasonably certain that an extension option will be exercised. The Group considers all relevant factors that create an economic incentive for it to exercise the extension. After the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to extend (refer note 17).

The Group has included the extension period as part of those premises leases where it is reasonably certain an extension option will be exercised.

5. REVENUE

		30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Revenue from sale of health and wellbeing products before marketing services provided by customers		2,781	3,260
Less marketing services provided by customers		(1,318)	(538)
Revenue from sale of health and wellbeing products		1,463	2,722
Revenue from sale of honey products		5,818	5,022
Revenue from agency services		602	529
Total revenue		7,883	8,273

The details above disaggregate the Group's revenue from contracts with customers into primary markets, and major product and service lines.

Revenue was generated from the following geographical regions:

		30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
New Zealand		6,474	7,842
USA		1,147	-
Europe		262	431
Total revenue		7,883	8,273

Revenue is allocated geographically based upon the jurisdiction in which the revenue is recognised for taxation purposes.

6. EXPENSES

The loss for the year includes the following expenses.

	Note	30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Salaries		(4,380)	(7,898)
Employer kiwisaver contributions		(106)	(163)
Directors' fees	29	(470)	(538)
Accounting and consulting		(79)	(125)
Shareholder expenses		(40)	(90)
Depreciation and amortisations:			
Depreciation of property, plant and equipment	16	(600)	(986)
Depreciation of right of use assets	17.1	(421)	(695)
Amortisation of customer relationship asset	19	(1,083)	(1,084)
Amortisation of other intangible assets	19	(3)	(7)
		(2,107)	(2,772)
Depreciation and amortisation are allocated as follows:			
Capitalised to biological WIP		576	647
Included in the operating loss		(1,531)	(2,125)
Finance expenses:			
Interest on lease liabilities	26	(17)	(62)
Interest on borrowings	26	(577)	(579)
		(594)	(641)
Auditor's remuneration:			
For the current year audit		(157)	(106)
For the prior year audit		-	(1)
Corporate finance service fee		(11)	-
For tax advice and returns		-	(9)
For general accounting advice		-	(5)
Total auditor's remuneration		(168)	(121)

7. SEGMENT INFORMATION

The Group:

- produces, sells, and markets health and wellbeing products ('sale of goods' segment) or acts as an agent on behalf of other health and wellbeing suppliers ('agency services' segment); and
- produces premium manuka honey ('honey' segment).

The Group has identified its operating segments based on the internal reports reviewed and used by the Chief Operating Decision Maker ('CODM'), being the Board of Directors, in assessing the Group's performance and in determining the allocation of resources.

The 'Operating EBITDA' measure is stated after depreciation and amortisation capitalised to biological WIP (note 6).

Head office expenses include costs related to the NZX listing.

	12 months to 30 June 2023					15 months to 30 June 2022				
	Sale of goods NZ\$000	Agency services NZ\$000	Honey NZ\$000	Head office NZ\$000	Total NZ\$000	Sale of goods NZ\$000	Agency services NZ\$000	Honey NZ\$000	Head office NZ\$000	Total NZ\$000
Revenue before marketing services provided by a customer	2,781	602	5,818	-	9,201	3,260	529	5,022	-	8,811
Less marketing services provided by customers	(1,318)	-	-	-	(1,318)	(538)	-	-	-	(538)
Total external revenue	1,463	602	5,818	-	7,883	2,722	529	5,022	-	8,273
Total inter-segment revenue	-	-	-	-	-	-	-	-	-	-
Total operating EBITDA	(2,365)	(161)	(1,228)	(1,392)	(5,146)	(1,913)	(310)	(1,881)	(1,548)	(5,652)
Finance income	-	-	1	3	4	-	-	6	13	19
Finance expenses	-	-	(591)	(3)	(594)	-	-	(633)	(8)	(641)
Amortisation of customer relationship asset	-	-	(1,083)	-	(1,083)	-	-	(1,084)	-	(1,084)
Depreciation and amortisation	(8)	(3)	(339)	(98)	(448)	(20)	(8)	(889)	(124)	(1,041)
Acquisition expenses	-	-	-	(115)	(115)	-	-	-	(368)	(368)
Fair value loss on harvested honey	-	-	(2,223)	-	(2,223)	-	-	(1,724)	-	(1,724)
Fair value loss on biological assets	-	-	(544)	-	(544)	-	-	(720)	-	(720)
Restructuring costs	-	-	(337)	-	(337)	-	-	(494)	-	(494)
Write down of assets held for sale	-	-	(128)	-	(128)	-	-	(543)	-	(543)
Impairment of goodwill	-	-	-	-	-	-	-	(9,120)	-	(9,120)
Impairment of customer relationship asset	-	-	(2,360)	-	(2,360)	-	-	(780)	-	(780)
Net loss before taxation	(2,373)	(164)	(8,832)	(1,605)	(12,974)	(1,933)	(318)	(17,862)	(2,035)	(22,148)
Income tax benefit	-	-	-	-	-	-	-	2,604	-	2,604
Net loss for the year	(2,373)	(164)	(8,832)	(1,605)	(12,974)	(1,933)	(318)	(15,258)	(2,035)	(19,544)

	2023					2022				
	Sale of goods NZ\$000	Agency services NZ\$000	Honey NZ\$000	Head office NZ\$000	Total NZ\$000	Sale of goods NZ\$000	Agency services NZ\$000	Honey NZ\$000	Head office NZ\$000	Total NZ\$000
Segment assets	3,495	243	22,482	730	26,950	2,255	147	31,590	5,464	39,456
Segment liabilities	695	123	13,639	560	15,017	396	43	14,471	447	15,357

7.1. Information about major customers

For the 12 months ended 30 June 2023 there were 2 customers who individually accounted for more than 10% of the Group's total sales (15 months ended 30 June 2022: 2 customers). Sales to these customers were \$2,087,994 and \$1,308,287 (2022: \$2,011,161 and \$1,852,980). These customers purchased goods or agency services.

8. TAXATION

8.1. Income tax recognised in profit or loss

The analysis of the income tax expense is as follows:

	30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Current income tax		
Current income tax charge	-	-
Deferred tax	-	(2,604)
Total income tax expense/(benefit) recognised in the current year	-	(2,604)

8.2. Reconciliation of income tax expense

The charge for the year can be reconciled to the loss before income tax as follows:

	30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Loss before income tax	(12,974)	(22,148)
Current year tax at the tax rate of 28% (2022: 28%)	(3,633)	(6,201)
Non-deductible expenses	188	2,868
Current tax losses not recognised	3,445	729
Income tax expense/(benefit)	-	(2,604)

8.3. Deferred tax

	Opening balance NZ\$000	Recognised in loss NZ\$000	Acquisition of subsidiaries NZ\$000	Closing balance NZ\$000
2023				
Deferred tax assets/(liabilities) in relation to:				
Customer relationship asset	(2,082)	964	-	(1,118)
Inventory fair value adjustments	1,472	(109)	-	1,363
Fair value loss on harvested honey	483	526	-	1,009
Write down of assets held for sale	152	(116)	-	36
Other	133	(112)	-	21
Deferred tax assets not recognised	(2,240)	(189)	-	(2,429)
Tax losses offset against deferred tax liability	2,082	(964)	-	1,118
	-	-	-	-
2022				
Deferred tax assets/(liabilities) in relation to:				
Customer relationship asset	-	522	(2,604)	(2,082)
Inventory fair value adjustments	-	(14)	1,486	1,472
Fair value loss on harvested honey	-	483	-	483
Write down of assets held for sale	-	152	-	152
Other	-	54	79	133
Deferred tax assets not recognised	-	(675)	(1,565)	(2,240)
Tax losses offset against deferred tax liability	-	2,082	-	2,082
	-	2,604	(2,604)	-
		2023	2022	
		NZ\$000	NZ\$000	
Tax losses				
Tax losses for which no deferred tax asset has been recognised		27,039	14,735	
Potential tax benefit @ 28%		7,571	4,126	

The Group did not recognise deferred income tax assets in relation to the losses disclosed above except to the extent they offset the deferred tax liability. The losses can be carried forward against future income subject to meeting the requirements of income tax legislation including those relating to shareholder continuity and business continuity (note 4.7).

9. EARNINGS PER SHARE

		2023 (12 months)	2022 (15 months)
Basic and diluted earnings/(loss) per share (NZ\$)		(0.009)	(0.029)
The losses and weighted average number of ordinary shares used in the calculation of loss per share are as follows:			
Loss from continuing operations (NZ\$000)		(12,974)	(19,544)
Weighted average number of ordinary shares used in the calculation of basic and diluted earnings per share ('000)		1,525,112	664,695

At 30 June 2023, there were no financial instruments that carried any shareholder dilution rights that were considered to be dilutive (2022: none). The 1,000,000 share options on issue in 2022 (refer note 24) were not considered to be dilutive due to the Group's loss.

10. CASH AND CASH EQUIVALENTS

		2023 NZ\$000	2022 NZ\$000
Cash at bank and on hand		913	5,370
		913	5,370

The carrying amount for cash and cash equivalents equals the fair value. Cash balances are on call and earn no interest.

11. TRADE AND OTHER RECEIVABLES

		2023 NZ\$000	2022 NZ\$000
Trade receivables		1,660	913
Other receivables		511	5
GST receivable		41	112
Prepayments		231	169
Total trade and other receivables		2,443	1,199

There has been no expected credit loss impairment to profit or loss in the period (2022: none).

The Group's trade receivables aging is as follows:

NZ\$000	Current	Less than 30 days past due	30 to 60 days past due	More than 60 days past due	Total
2023					
Trade receivables	675	551	50	384	1,660
Loss allowance	-	-	-	-	-
2022					
Trade receivables	736	87	23	67	913
Loss allowance	-	-	-	-	-

The standard credit period on sales of goods is 30 or 60 days on the provision of the sale of goods or rendering of agency services.

In determining the recoverability of a trade receivable, the Group considers any change in the credit quality of the trade receivable from the date credit was initially granted up to the end of the reporting period. The Group has 2 main customers who are both assessed as creditworthy. The Group maintains close working relationships with these customers. The Group does not hold any collateral over these balances.

The Group determines the expected credit losses on receivables by using a provision matrix, estimated based on historical credit loss experience based on the past due status of the debtors, adjusted as appropriate to reflect current conditions and estimates of future economic conditions.

Other Receivables includes amounts due from the sale of assets. These are repayable in instalments over periods of up to 2 years.

12. INVENTORIES

		2023 NZ\$000	2022 NZ\$000
Raw materials		10,777	13,069
Finished goods		2,686	3,119
Packaging materials		1,296	605
		14,759	16,793

No inventory was written off to profit and loss in the period (2022: nil). Inventory expensed in the period was \$4,767,197 (2022: \$4,899,517).

The Group's inventory net realisable value provision at 30 June 2023 was \$2.6 million (2022: \$3.0 million). The change in the provision was reversed to profit or loss in the year upon the sale of the related inventory.

13. ASSETS HELD FOR SALE

		2023 NZ\$000	2022 NZ\$000
Property, plant and equipment		93	450
Biological assets		-	613
		93	1,063

		2023 NZ\$000	2022 NZ\$000
At 1 July		1,063	-
Reclassified from property, plant & equipment (note 16):			
- cost		335	744
- accumulated depreciation		(70)	(104)
Write down of assets held for sale		(61)	(190)
Net book value reclassified from property, plant & equipment		204	450
Reclassified from biological assets (note 15)		302	965
Write down of assets held for sale		(67)	(352)
Net book value reclassified from biological assets		235	613
Sale of assets		(1,409)	-
Balance at 30 June		93	1,063

14. BIOLOGICAL WORK IN PROGRESS

		2023 NZ\$000	2022 NZ\$000
At 1 July		698	-
Acquisition of subsidiaries		-	1,437
Current period beekeeping costs		2,349	7,239
Fair value loss on harvested honey		(2,223)	(1,724)
Honey recognised as inventory on harvest		(683)	(6,952)
Beekeeping costs related to next harvest		160	698
Beekeeping costs expensed due to restructure		(141)	-
At 30 June		160	698

15. BIOLOGICAL ASSETS

		2023 NZ\$000	2022 NZ\$000
Bees:			
At 1 July		1,598	-
Acquisition of subsidiaries		-	3,283
Reclassified to assets held for sale (note 13)		(302)	(965)
Fair value loss on biological assets		(544)	(720)
At 30 June		752	1,598

The bees biological assets consist of hives and nucs.

		2023 number of	2022 number of
Hives:			
At 1 July		8,950	-
Acquisition of subsidiaries		-	15,595
Reduction in operational hives		(3,047)	(2,995)
Hives classified as assets held for sale (note 13)		(1,691)	(3,650)
Hives included in biological assets at 30 June		4,212	8,950

Nucleus colonies (Nucs):			
At 1 July		-	-
Acquisition of subsidiaries		-	3,660
Reduction in operational nucs		-	(1,360)
Nucs classified as assets held for sale (note 13)		-	(2,300)
Nucs included in biological assets at 30 June		-	-

The Group is exposed to some risks related to owning bees, primarily the risk of damage from climatic changes and diseases. The Group has processes in place aimed at monitoring and mitigating those risks, through hiring of experienced beekeepers, the intensive maintenance of beehives and disease prevention programmes.

Fair value hierarchy

The Group's bees are level 3 on the fair value hierarchy, being calculations for which inputs are not based on observable market data (unobservable inputs).

The Group has valued the biological assets based on market sales price information and the Group's own sales of hives. The fair value per hive is \$179 (2022: \$179).

16. PROPERTY, PLANT AND EQUIPMENT

	Plant & equipment NZ\$000	Vehicles NZ\$000	Office equipment & furniture NZ\$000	Leasehold improvements NZ\$000	Total NZ\$000
Cost:					
At 1 April 2021	10	-	95	31	136
Additions	81	208	37	1	327
Acquisition of subsidiaries	3,731	968	62	335	5,096
Transferred to assets held for sale	(406)	(338)	-	-	(744)
Disposals	(2)	(133)	-	-	(135)
At 30 June 2022	3,414	705	194	367	4,680
Additions	31	-	4	-	35
Transferred to assets held for sale	(314)	(21)	-	-	(335)
At 30 June 2023	3,131	684	198	367	4,380
Accumulated depreciation:					
At 1 April 2021	(4)	-	(35)	(6)	(45)
Depreciation expense	(660)	(210)	(68)	(48)	(986)
Transferred to assets held for sale	41	63	-	-	104
Disposals	-	35	-	-	35
At 30 June 2022	(623)	(112)	(103)	(54)	(892)
Depreciation expense	(410)	(113)	(36)	(41)	(600)
Transferred to assets held for sale	59	11	-	-	70
At 30 June 2023	(974)	(214)	(139)	(95)	(1,422)
Carrying amount:					
At 30 June 2023	2,157	470	59	272	2,958
At 30 June 2022	2,791	593	91	313	3,788
At 1 April 2021	6	-	60	25	91

17. LEASES

17.1. Right-of-use asset

The Group leases warehouse and administration premises, and land used for hive placements.

	Premises NZ\$000	Hive placements NZ\$000	Total NZ\$000
Cost:			
At 1 April 2021	226	-	226
Additions	296	313	609
Acquisition of subsidiaries	934	1,071	2,005
Lease modifications	(82)	(626)	(708)
At 30 June 2022	1,374	758	2,132
Additions	174	186	360
Lease modifications	(332)	(224)	(556)
At 30 June 2023	1,216	720	1,936
Accumulated amortisation:			
At 1 April 2021	(50)	-	(50)
Depreciation expense	(371)	(324)	(695)
At 30 June 2022	(421)	(324)	(745)
Depreciation expense	(284)	(137)	(421)
At 30 June 2023	(705)	(461)	(1,166)
Carrying Amount:			
At 30 June 2023	511	259	770
At 30 June 2022	953	434	1,387
At 1 April 2021	176	-	176

The Group leases warehouse and administration premises, and land used for hive placements.

17.2. Lease liability

		2023 NZ\$000	2022 NZ\$000
Maturity analysis - contractual undiscounted cash flows			
Up to one year		356	381
One to two years		335	526
Two to five years		156	492
More than five years		-	77
Total undiscounted lease liabilities at 30 June		847	1,476
Lease liabilities included in the Consolidated Statement of Financial Position			
Current		334	316
Non-current		472	1,041
		806	1,357

At the reporting date the Group had 4 property leases with an average remaining term of 2.6 years (2022: 3.75 years). The Group also had 7 land access leases with an average remaining term of 1.86 years (2022: 0.75 years).

The average IBR rate is 3.6% (2022: 3.63%).

Short term lease expenses included in operating loss were \$1,122,000 (2022: \$1,122,000).

18. GOODWILL

		2023 NZ\$000	2022 NZ\$000
Balance at 1 July			
Recognised on acquisition of subsidiary		-	9,120
Impairment losses for the period (note 19.1)		-	(9,120)
Balance at 30 June		-	-

19. OTHER INTANGIBLE ASSETS

	Customer relationship NZ\$000	Website NZ\$000	Trademarks & domains NZ\$000	Total NZ\$000
Cost:				
At 1 April 2021	-	26	61	87
Additions	-	-	23	23
Acquisition of subsidiaries	9,300	-	-	9,300
At 30 June 2022	9,300	26	84	9,410
Additions	-	-	12	12
At 30 June 2023	9,300	26	96	9,422
Accumulated amortisation and impairment:				
At 1 April 2021	-	(14)	-	(14)
Amortisation expense	(1,084)	(7)	-	(1,091)
Impairment of intangible asset (note 19.1)	(780)	-	-	(780)
At 30 June 2022	(1,864)	(21)	-	(1,885)
Amortisation expense	(1,083)	(3)	-	(1,086)
Impairment of intangible asset (note 19.1)	(2,360)	-	-	(2,360)
At 30 June 2023	(5,307)	(24)	-	(5,331)
Carrying Amount:				
At 30 June 2023	3,993	2	96	4,091
At 30 June 2022	7,436	5	84	7,525
At 1 April 2021	-	12	61	73

19.1. Impairment testing for cash-generating units containing goodwill and the customer relationship asset

Given the financial performance of the Honey segment did not meet internal forecast expectations, the Board undertook a value in use impairment test at 30 June 2023 and reviewed sensitivity analysis relating to the carrying value of the customer relationship asset (2022: impairment test as at 31 March 2022 to assess carrying value of the goodwill and customer relationship assets).

The Group considered the future cash flows arising out of the sale of Manuka Honey through the Honey segment. As a result of the completion of discounted cashflow modelling, the Board assessed the value of the Honey CGU as \$21.1 million (2022: \$29.0 million). The Board concluded that it was appropriate for the Group to recognise impairments in value in the goodwill and the customer relationship asset arising from the King Honey acquisition as set out below:

		2023 NZ\$000	2022 NZ\$000
Impairment losses:			
Impairment of customer relationship asset		(2,360)	(780)
Impairment of goodwill (note 18)		-	(9,120)
		(2,360)	(9,900)

Value in use was determined by discounting the future cash flows generated from the continuing use of the CGU and was based on the following key assumptions:

		2023	2022
Years assessed in cash projections		2024 - 2028	2023 - 2027
Anticipated annual revenue growth		3% - 20%	26% - 39%
Anticipated annual overhead expense increase		3%	2%
Pre-tax discount rate		18.2%	16.5%
Terminal growth rate		3%	3%

Cash flows were projected on actual operating results, the 12-month budget, multi-year forecasts and business plan.

The discount rate selected reflects the level of uncertainty in relation to the future revenue from the Honey CGU.

The growth rate applied in years 2029-2037 (years 6 to 14 in the model) to revenue is 3% and to costs is 2-3%. These rates reflect the long-term growth rates of the markets in which the revenues are earned and the costs expended. These years have been included in the calculation to forecast a tax outflow in the terminal year where the terminal value has been derived, as existing tax losses are expected to be utilised against taxable profits in earlier years.

20. TRADE AND OTHER PAYABLES

		2023 NZ\$000	2022 NZ\$000
Trade payables		946	482
Accruals		593	626
Other payables		238	658
		1,777	1,766

21. BORROWINGS

		2023 NZ\$000	2022 NZ\$000
Banks loans		7,034	7,034
Subordinated note		5,400	5,200
		12,434	12,234
Current		7,248	942
Non-current		5,186	11,292
		12,434	12,234

The Group has two bank loans from the Bank of New Zealand. A customised average rate loan facility (CARL) of \$2,908,420 (2022: \$3,015,980) and a fixed rate loan of \$4,125,809 (2022: \$4,286,125). The loans were taken out on 30 June 2021 and are for five years, ending 29 June 2026. The loans are secured over all property of Me Today Manuka Honey Limited, the parent company of King Honey Limited and a subsidiary of Me Today Limited.

The CARL facility monthly repayments consist of a fixed principal repayment plus interest based on a floating rate that is adjusted monthly. The average annual interest on the CARL facility rate during the reporting period was 6.58% (2022: 3.91%). Interest on the fixed rate loan is fixed at 2.51% per annum and the loan is repaid by monthly instalments over the term of the loan. The Group had a repayment holiday from June 2022 to August 2023. The bank has also agreed to suspend its earnings-related covenants until 31 August 2023 at which stage covenants will be re-assessed in line with the FY24 budget. The Group was compliant with applicable covenants at 30 June 2023.

Under the terms of the sale and purchase agreement for the acquisition of King Honey it was agreed that \$5,000,000 of the purchase price would be left payable to the vendors, the Jarvis Trust, as a subordinated note. As at 30 June 2023 the subordinated loan was repayable in three years from the acquisition date of 30 June 2021 and is classified in the Consolidated Statement of Financial Position as a current liability. The note is secured over all property of Me Today Manuka Honey Limited. This security interested ranks behind any security interest in favour of the Bank of New Zealand pursuant to the bank loan agreements noted above, but ahead of any other indebtedness of Me Today Manuka Honey Limited. Subsequent to the reporting date the parties have agreed to extend the repayment date of the subordinated note for nine months to 31 March 2025. A condition of this extension is that the Group cannot increase its indebtedness with the BNZ above \$9.5 million without the consent of the Jarvis Trust. Interest of 4% per annum is payable annually in arrears until 30 June 2024. Interest of 8% per annum is payable from 1 July 2024 onwards. The extension is subject to Me Today obtaining shareholder approval under NZX Listing Rule 5.2 (related party transactions) or a waiver of that rule.

The Group currently has available overdraft facilities of \$5 million (2022: \$5 million). The interest rate on this facility at 30 June 2023 was 9.91% per annum.

22. SHARE CAPITAL

	2023		2022	
	Voting ordinary shares '000	Non-voting ordinary shares '000	Voting ordinary shares '000	Non-voting ordinary shares '000
Number of ordinary shares:				
Ordinary shares as at 1 July	1,163,697	287,086	412,278	-
Issue of shares as settlement of purchase price	-	-	113,636	-
Ordinary shares issued during the period	92,980	-	924,903	-
Ordinary shares reclassified as non-voting	39,051	(39,051)	(287,086)	287,086
Share buy back and cancellation	-	-	(34)	-
Ordinary shares as at reporting date	1,295,728	248,035	1,163,697	287,086

On 6 July 2022 the Company issued 75,264,609 fully paid ordinary shares for \$752,646 as a part placement of the shortfall from its rights issue undertaken in June 2022. The Company agreed with MTL Securities Limited to contemporaneously reclassify 39,051,043 of its non-voting shares as quoted shares to preserve MTL Securities Limited's holding and control of voting rights at 34.16%. The new shares issued have consequentially reduced MTL Securities Limited's economic rights to 44.86%.

On 28 June 2023 the Company issued 17,715,461 fully paid ordinary shares in the favour of BB Promotions Limited, Sarah Walker, independent directors and a non-executive director. Shares issued to BB Promotions Limited and Sarah Walker are in accordance with the terms of the relevant agreements for promotional services.

All voting ordinary shares on issue are fully paid and rank equally with one vote attached to each share.

All non-voting ordinary shares are fully paid.

23. SHARE BASED PAYMENTS RESERVE

		30 Jun 2023 NZ\$000	30 Jun 2022 NZ\$000
Balance as at 1 July		77	110
Share options granted (note 24)		-	30
Share options expired (note 24)		(13)	(26)
Share based payments for promotional services		95	140
Shares issued in period		(159)	(177)
Balance at reporting date		-	77

The Group has entered into two Ambassador Agreements for the provision of promotional services. A portion of the consideration payable for the promotional services is settled by the issue of shares. For one ambassador, who is a related party, shares are issued twice yearly with a total of 1,244,444 ordinary shares to be issued each year at an issue price of \$0.09 per share. 1,111,111 shares are to be issued annually under an agreement with a three-year term. For the other ambassador 133,333 shares are issued annually under an agreement with a two-year term.

All share-based payments were included in promotional expenses.

24. SHARE OPTIONS

	2023		2022	
	Number of Options	Weighted average exercise price	Number of Options	Weighted average exercise price
Balance as at 1 July	1,000,000	\$0.09	3,000,000	\$0.09
Granted during the period	-	-	-	-
Exercised during the period	-	-	-	-
Expired during the period	(1,000,000)	\$0.09	(2,000,000)	\$0.09
Balance at 30 June	-	-	1,000,000	\$0.09

At 30 June 2022 BB Promotions Limited, a related party to the Group (refer note 29.4), held options on 1,000,000 ordinary shares of the Company. Each option could be converted into one ordinary share of the Company on exercise. No amounts were paid or payable by BB Promotions Limited on receipt of the options. The options carried no rights to dividends and no voting rights. The options expired during the 2023 financial year.

		2023 NZ\$000	2022 NZ\$000
Share based payments are included in:			
Promotional costs		95	30

25. RECONCILIATION OF LOSS AFTER TAXATION WITH CASH FLOW FROM OPERATING ACTIVITIES

	30 Jun 2023 (12 months) NZ\$000	30 Jun 2022 (15 months) NZ\$000
Net loss after taxation	(12,974)	(19,544)
Adjustments for:		
Depreciation and amortisation	2,107	2,771
Interest on lease liabilities	17	62
Interest on borrowings	577	579
Impairment of goodwill	-	9,120
Impairment of customer relationship asset	2,360	780
Acquisition costs	114	367
Fair value loss on biological assets	544	720
Write down of assets held for sale	128	543
Share-based payments	209	242
Income tax benefit	-	(2,604)
Movements in working capital		
(Increase) / decrease in trade and other receivables	(1,244)	(778)
(Increase) / decrease in inventory	2,034	(15,859)
(Increase) / decrease in biological work in progress	538	(698)
Decrease / (increase) in taxation receivable	24	(12)
Increase / (decrease) in trade and other payables	11	1,139
Movement in working capital on acquisition of subsidiaries	-	11,446
Net cash outflows from operating activities	(5,555)	(11,726)

26. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES

	2023 NZ\$000	2022 NZ\$000
Borrowings:		
At 1 July	12,234	-
<i>Cash:</i>		
Proceeds from bank borrowings	-	8,500
Payment of principal on borrowings	-	(1,466)
Interest paid on borrowings	(377)	(379)
<i>Non-cash:</i>		
On acquisition of subsidiaries	-	5,000
Interest on borrowings	577	579
At 30 June	12,434	12,234

	2023 NZ\$000	2022 \$000
Lease liabilities:		
At 1 July	1,357	193
<i>Cash:</i>		
Payment of lease liabilities principal	(355)	(742)
Interest paid on lease liabilities	(17)	(62)
<i>Non-cash:</i>		
Lease liabilities recognised	186	609
On acquisition of subsidiaries	-	2,005
Lease modifications	(382)	(708)
Interest on lease liabilities	17	62
At 30 June	806	1,357

27. SUBSIDIARIES AND OTHER INVESTMENTS

Name	Principal activity	Equity holding	
		2023	2022
Subsidiaries:			
The Good Brand Company Limited	Sale of health & wellbeing products	100%	100%
Me Today NZ Limited	Production & sale of health & wellbeing products	100%	100%
Today Limited	Non-trading entity	100%	100%
Me Today EU Limited	Sale of health & wellbeing products	100%	100%
Me Today UK Group Limited	Sale of health & wellbeing products	100%	100%
Me Today Manuka Honey Limited	Investment in King Honey Limited	100%	100%
King Honey Limited	Sale of manuka honey products	100%	100%
Me Today AU Pty Limited	Non-trading entity	100%	100%
Manuka Wellness Limited	Non-trading entity	100%	100%
King Honey Health Products Limited	Non-trading entity	100%	100%
Pure Manuka NZ Limited	Non-trading entity	100%	100%
Bee Plus Manuka NZ Limited	Non-trading entity	100%	100%
Me Today USA Inc.	Sale of health, wellbeing and honey products	100%	100%
Other investments:			
Bee Plus New Zealand Limited	Brand ownership. Non trading	15%	15%

All subsidiaries are domiciled in New Zealand, with the exception of Me Today EU Limited which is domiciled in Ireland, Me Today UK Group Limited which is domiciled in England, Me Today USA Inc. which is domiciled in the United States and Me Today Pty which is domiciled in Australia. All subsidiaries have a reporting date of 30 June.

28. FINANCIAL INSTRUMENTS

The Group's activities expose it to a variety of financial risks: market risk (including currency risk and interest rate risk), credit and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on its financial performance.

Risk management is carried out under policies approved by the Board of Directors. The Board provides written principles for overall risk management as well as policies covering specific areas such as interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments.

The Group has entered into a number of non-derivative financial instruments all of which are classified as financial assets and liabilities at amortised cost. The carrying values of these items approximate their fair value and represent the maximum exposures for each type of financial instrument. They are listed as follows:

	Note	2023 NZ\$000	2022 NZ\$000
Financial assets at amortised cost			
Cash and cash equivalents	10	913	5,370
Trade receivables	11	1,660	913
Other receivables	11	511	-
Total financial assets		3,084	6,283

The fair value of cash and cash equivalents and trade receivables are determined to be equivalent to their carrying value due to the short-term nature of these balances.

	Note	2023 NZ\$000	2022 NZ\$000
Financial liabilities at amortised cost			
Trade payables and other liabilities	20	1,777	1,766
Banks loans	21	7,034	7,034
Subordinated note	21	5,400	5,200
Total financial liabilities		14,211	14,000

The fair value of trade payables and other liabilities, and the subordinated note, are determined to be equivalent to their carrying value due to the short-term nature of these balances.

The fair value of the bank loans is \$6,618,000 (2022: \$6,728,000).

The Group does not have any derivative financial instruments (2022: nil).

28.1. Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control the market risk exposures within acceptable parameters, while optimising the return on risk. There is minimal market risk.

28.2. Cash flow and fair value interest rate risk

The Group's interest rate risk arises from interest on borrowings at variable rates. The Group has no interest-bearing cash and cash equivalent bank accounts.

The fixed rate bank loan and the subordinated note (see note 21) have interest rates that are fixed for the life of the loan. The BNZ CARL is the only borrowing with a variable interest rate (see note 21). The Group's exposure to a change in interest rates is therefore currently limited to the borrowings under the BNZ CARL facility. The table below shows the impact that a 1% movement in the current interest rate on the BNZ CARL facility would have on the per annum interest expense.

	Facility balance 2023 NZ\$000	Interest impact Rate (+/-1%) NZ\$000
BNZ CARL facility	2,908	29/(29)

28.3. Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises from cash and cash equivalents, deposits with banks and the Group's receivables from customers. The Group's maximum credit risk is represented by the carrying value of these financial assets. The credit risk associated with cash transactions and deposits is managed through the Group's policies that limit the use of counterparties to high credit quality financial institutions.

28.4. Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as and when they fall due. The Group's liquidity risk management includes maintaining sufficient cash reserves to meet future commitments. Refer to note 4.1 in relation to going concern.

The following table provides a maturity analysis of the Group's remaining contractual cash flows relating to financial liabilities. Contractual cash flows include contractual undiscounted principal and interest payments

	Carrying amount NZ\$000	Contractual cash flows NZ\$000	Payable 0-6 months NZ\$000	Payable 6-12 months NZ\$000	Payable 1-2 years NZ\$000	Payable 2-5 years NZ\$000
Non-derivative financial liabilities						
2023						
Trade and other payables	1,777	1,777	1,665	112	-	-
Borrowings	12,434	13,293	911	6,862	2,498	3,022
Lease liability	806	927	242	122	335	228
	15,017	15,997	2,818	7,096	2,833	3,250
2022						
Trade and other payables	1,766	1,766	1,766	-	-	-
Borrowings	12,234	13,290	270	926	7,417	4,677
Lease liability	1,357	1,389	386	166	421	416
	15,357	16,445	2,422	1,092	7,838	5,093

28.5. Capital risk management

The Group's objectives when managing capital are to safeguard their ability to continue as a going concern, so that they can continue to provide returns to shareholders and benefits for other stakeholders and to maintain an optimal capital structure that reduces the cost of capital.

29. RELATED PARTIES

29.1. Directors

The names of persons who are directors of the Company are; Grant Baker (Chairman), Hannah Barrett, Roger Gower, Michael Kerr, Richard Pearson, Stephen Sinclair, and Antony Vriens.

29.2. Key management personnel compensation

Key management personnel compensation is set out below. The key management personnel are all the directors of the Company.

Directors were paid directors' fees of \$470,000 (15 months to 30 June 2022: \$538,000). In the period to 30 June 2023 \$70,214 of the remuneration due to the independent directors was settled by the issue of 1,312,266 shares in the Company (15 months to 30 June 2022: \$71,572 by the issue of 1,312,266 shares in the Company). At 30 June 2022 \$14,062 was payable to the independent directors and was subsequently settled by the issue of shares in the Company.

At 30 June 2023 \$9,104 was payable to Bakers Consultants Limited, a company owned by Grant Baker, for directors fees (2022: nil).

At 30 June 2023 \$6,563 was payable to Mei Mei Limited, a company owned by Richard Pearson, for directors fees (2022: \$7,000).

Michael Kerr received total remuneration of \$250,000 in 2023 in his role as CEO (15 months to 30 June 2022: \$281,000).

A company owned by Stephen Sinclair received \$125,000 in consulting fees (15 months to 30 June 2022: \$156,250).

29.3. Related entities

MTL Securities Limited is an entity owned and controlled by M & N Kerr Holdings, of which Michael Kerr is a director, and Velocity Capital, of which Grant Baker and Stephen Sinclair are directors. MTL Securities Limited holds 34.16% of the voting ordinary shares, and 44.86% of the total voting and non-voting ordinary shares in Me Today Limited.

29.4. Related party transactions

In the year to 30 June 2023, the Company issued 3,277,150 ordinary shares to each of Antony Vriens, Hannah Barrett and Roger Gower and 6,117,346 to Richard Pearson, in part settlement of their directors' remuneration. In the 15 months to 30 June 2022, the Company issued 965,613 ordinary shares

to Antony Vriens, Hannah Barrett and Roger Gower in part settlement of their directors' remuneration.

The Company issued 712,575 ordinary shares to Roger Gower and 3,411,778 ordinary shares to Antony Vriens as part of the retail offer to investors on 29 June 2022 for \$7,126 and \$34,118 respectively.

On 15 June 2020 the Company entered into an Ambassador Agreement with BB Promotions Limited for a term of three years. BB Promotions Limited is a related party to the Group, as the shareholder and director of BB Promotions Limited, B Barrett, is married to H Barrett, a director of the Company. Under the terms of the agreement, BB Promotions Limited agreed to provide promotional services to the Company in exchange for the payment of \$50,000 per annum, the issue by the Company of ordinary shares to BB Promotions Limited to the value of \$100,000 per annum, and the granting of 3,000,000 options to purchase ordinary shares in the Company (as detailed in notes 24). Share based payments for promotion services shown in note 23 includes \$62,500 in relation to the Ambassador Agreement with BB Promotions Limited.

Hannah Barrett received \$6,250 for providing marketing services to the Group (15 months to 30 June 2022: \$18,750).

29.5. Share placement subscription agreement

On 26 November 2021, Me Today, the TW Jarvis (No. 1) Family Trust ("Jarvis Trust") and MTL Securities Limited ("MTL") entered into a share placement subscription agreement under which the Jarvis Trust and MTL agreed to invest additional cash of \$6 million through a share placement, conditional upon shareholder approval. The shares were issued at 8.8 cents per share, the same issue price for capital raised as part of the King Honey acquisition and reflecting their respective shareholdings. MTL Securities agreed to contribute \$3.75 million and Jarvis Trust \$2.25 million. Shareholders approved the share placement on 18 March 2022.

On 22 March 2022 the Company issued 42,613,636 fully paid ordinary shares to MTL Securities Limited and 25,568,182 fully paid ordinary shares to the trustees of TW Jarvis (No. 1) Trust.

Jarvis Trust is a substantial security holder in Me Today and is the previous vendor of King Honey Limited. MTL is a substantial security holder, and the largest shareholder, in Me Today. MTL is an entity owned and controlled by M & N Kerr Holdings, of which Michael Kerr is a director, and Velocity Capital, of which Grant Baker and Stephen Sinclair are directors.

30.CONTINGENT LIABILITIES

There are no contingent liabilities as at 30 June 2023 (2022: nil).

31.COMMITMENTS

The Company had no commitments for future capital expenditure as at 30 June 2023 (2022: nil).

32.EVENTS SUBSEQUENT TO REPORTING DATE

On 23 August 2023 the Group's bank confirmed its continuance of existing facilities subject to further review no later than 31 August 2024 in conjunction with the FY24 audited financial statements and FY25 budget. Facilities will remain on an interest only basis until 31 August 2024. The requirement for an amortisation programme will be considered at that time in conjunction with the FY25 budget. The bank also confirmed covenant requirements continue to be amended to extend the suspension of earnings-related covenants until 31 August 2024.

Subsequent to the reporting date the Board has decided to further reduce beekeeping operations with a view to reducing total hive numbers to below 2,000.

On 28 August 2023 the Group entered into an agreement with the Jarvis Trust to extend the repayment date of the subordinated note for nine months to 31 March 2025. A condition of this extension is that the Group cannot increase its indebtedness with the BNZ above \$9.5m without the consent of the Jarvis Trust. Interest of 4% per annum is payable annually in arrears until 30 June 2024. Interest of 8% per annum is payable from 1 July 2024 onwards.





me | today®

Independent Auditor's Report

TO THE SHAREHOLDERS OF ME TODAY LIMITED





Independent Auditor's Report

TO THE SHAREHOLDERS OF ME TODAY LIMITED

Opinion

We have audited the consolidated financial statements of Me Today Limited ("the Company") and its subsidiaries (together, "the Group"), which comprise the consolidated statement of financial position as at 30 June 2023, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at 30 June 2023, and its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with New Zealand equivalents to International Financial Reporting Standards ("NZ IFRS") and International Financial Reporting Standards ("IFRS").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (New Zealand) ("ISAs (NZ)"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with Professional and Ethical Standard 1 *International Code of Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand)* issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

In addition to audit services, our firm provided other services in the areas of corporate finance services. BDO partners and staff also transact with the Group on normal trading terms throughout the year. The engagement and trading transactions have not impaired our independence as auditor of the Group. We have no other relationship with, or interests in, the Company or its subsidiaries.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Impairment of intangible assets

Key Audit Matter

The Group had a customer relationship intangible asset of \$3.9m at 30 June 2023, which is required to be assessed for impairment indicators as it is a non-financial asset.

Given the financial performance of the Honey cash generating unit did not meet internal forecast expectations, management performed a formal impairment test to determine the recoverable amount of the cash generating asset.

We identified the calculation of the recoverable amount as a key audit matter to our audit due to the significance of the balance to the financial statements and the key inputs and assumptions that are subject to significant management judgement and estimation uncertainty.

See note 19.1 to the financial statements.

How The Matter Was Addressed in Our Audit

- We obtained management's value in use calculation prepared at 30 June 2023, and critically evaluated the key inputs and assumptions. The key inputs included forecast revenue, gross margin, costs, working capital assumptions, tax outflows and discount rate.
- We agreed the forecasts used to the management approved budget.
- We obtained management's discount rate calculation, prepared by an external valuation expert. We considered the objectivity and competence of the expert.
- We engaged our internal valuation expert to review the value in use calculation against valuation industry techniques and the discount rate used.
- We compared the carrying value of the assets to the recoverable amount determined by the impairment test that calculated the impairment charge of \$2.4m.

Inventory net realisable value

Key Audit Matter

At the reporting date, management is required to consider if the Group's inventories are carried at the lower of cost or net realisable value.

Management has identified that based on near term forecast demand that there is currently excess inventory held and that therefore there may be issues in achieving the carrying value of this inventory.

They have estimated this excess quantity, by grade of honey, and have considered its net realisable value by reference to the likely manner in which it will be used. Management recorded an inventory net realisable value provision in this respect of \$2.6m (2022: \$3.0m).

We identified the determination of the net realisable value by management as a key audit matter to our audit due to the significance of the balance to the financial statements and the significant judgement involved in determining these estimates.

See note 12 to the financial statements. The Group's critical accounting estimate and judgement regarding inventory net realisable value is disclosed in note 4.4 to the financial statements.

How The Matter Was Addressed in Our Audit

- We obtained management's calculation of the required net realisable value provision against the carrying value of inventories. We re-calculated the excess inventory by grade by reference to quantity held and forecast demand which was agreed to management approved budgets.
- We obtained management's rationale for the expected use of this excess inventory and the net realisable value provision held. We challenged management with respect to their rationale and on the existence of other alternative uses for the inventories.
- We agreed the net realisable values used in the management calculation to supporting documentation and re-calculated the net realisable value provision required.

Other Information

The directors are responsible for the other information. The other information comprises the Market Announcement on the Me Today results for the year ended 30 June 2023 (but does not include the consolidated financial statements and our auditor's report thereon), which we obtained prior to the date of this auditor's report, and the Annual Report, which is expected to be made available to us after that date.

Our opinion on the consolidated financial statements does not cover the other information and we do not and will not express any form of audit opinion or assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to the directors.

Directors' Responsibilities for the Consolidated Financial Statements

The directors are responsible on behalf of the Group for the preparation and fair presentation of the consolidated financial statements in accordance with NZ IFRS and IFRS, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible on behalf of the Group for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.



Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (NZ) will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decisions of users taken on the basis of these consolidated financial statements.

A further description of our responsibility for the audit of the financial statements is located on the External Reporting Board's website at:

<https://www.xrb.govt.nz/standards-for-assurance-practitioners/auditors-responsibilities/audit-report-1>.

This description forms part of our auditor's report.


Who we Report to

This report is made solely to the Company's shareholders, as a body. Our audit work has been undertaken so that we might state those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's shareholders, as a body, for our audit work, for this report or for the opinions we have formed.

The engagement partner on the audit resulting in this independent auditor's report is Chris Neves.



BDO Auckland
Auckland
New Zealand
29 August 2023



HIGH DOSE

Ashwagandha ³⁰⁰⁰

3000mg Ashwagandha Root
For Your Daily Stress Care

today®

me

Corporate Governance Statement



Corporate Governance Statement

FOR THE 12 MONTHS ENDED 30 JUNE 2023

The Board is responsible for the overall corporate governance of the Company, and it recognises the need for the highest standards of behaviour and accountability. The Board develops strategies for the Company, reviews strategic objectives and monitors the Company's performance against those objectives. The overall goals of the corporate governance process are to:

- drive shareholder value;
- assure a prudential and ethical base to the Company's conduct and activities; and
- ensure compliance with the Company's legal and regulatory obligations.

The Governance Principles adopted by the Board are designed to achieve these goals.

The full content of the Company's Governance Code and related policies and charters, can be found at the following link (<https://www.metodayinvestors.com/corporate-governance/>).

This statement is a summary of the Corporate Governance arrangements approved and observed by the Board as at 30 June 2023. The statement has been approved by the Board.

CODE OF ETHICS

The board has documented a code of ethics, which can be found at <https://www.metodayinvestors.com/corporate-governance/>, detailing the ethical standards to which Me Today Limited's directors and employees are expected to adhere.

ROLE OF THE BOARD

The Board assumes the following primary responsibilities:

- formulation and approval of the strategic direction, objectives and goals of the Company;
- monitoring the financial performance of the Company, including approval of the Company's financial statements;
- ensuring that adequate internal control systems and procedures exist and that compliance with these systems and procedures is maintained;
- review of performance and remuneration of directors and executive officers; and
- establishment and maintenance of appropriate ethical standards for the Company to operate by.

A formal Governance Code, which can be found at <https://www.metodayinvestors.com/corporategovernance/>, has been adopted by the Board and outlines directors' responsibilities. The Board internally evaluates its performance and continues to assess the size, diversity and skills of the Board.

BOARD COMPOSITION

In accordance with the Company's constitution the Board will comprise not less than three directors. The Board will be comprised of a mix of persons with complementary skills appropriate to the Company's objectives and strategies.

The Board currently comprises seven Directors. For the 12 months ended 30 June 2023, Hannah Barrett, Roger Gower and Antony Vriens are considered Independent directors. The Board considers that, although it does not have a majority of independent board members per the NZX Corporate Governance Code Recommendation, it has the right balance for the current size and structure of the Company.

Independence of directors is assessed against the requirements of the NZX Listing Rules, NZX Corporate Governance Code, and the factors included in the Company's Governance Code.

Although the Chair of the board is not Independent, the board considers that for the size and structure of the Company, an Independent Chair is not required at this time.

BOARD MEETINGS

The board aims to meet at least 11 times each year for scheduled meetings. Additional meetings are held where specific matters require attention between scheduled meetings. Board meetings are used to monitor, challenge, develop and fully understand business and operational issues.

The following table shows director attendance at meetings during the 12 month period ended 30 June 2023.

	Board	Audit, Finance & Risk Committee
G Baker	11	n/a
H Barrett	10	3
R Gower	10	3
M Kerr	11	2
R Pearson	9	n/a
S Sinclair	11	3
A Vriens	10	n/a

CRITERIA FOR BOARD MEMBERSHIP

When a vacancy arises, the Board will identify candidates with a mix of diversity, capabilities and perspectives considered necessary for the Board to carry out its responsibilities effectively. A director appointed by the Board must stand for election at the next Annual Meeting. No director shall hold office (without re-election) past the third annual meeting following that directors' appointment or three years, whichever is longer. Retiring directors are eligible for re-election.

BOARD COMMITTEES

The Board has established an Audit, Finance and Risk Committee and a Remuneration, Nomination and Health & Safety Committee.

The Audit, Finance and Risk Committee operates under a Charter approved by the Board and is accountable to the Board for: the business relationship with, and the independence of, external auditors; the reliability and appropriateness of the disclosure of the financial statements and external financial communication; and the maintenance of an effective business risk management framework including compliance and internal controls. The Audit, Finance and Risk Committee is chaired by Roger Gower with Stephen Sinclair, Hannah Barrett as members. Mr Gower and Ms Barrett are Independent Directors. Only committee members attend Audit, Finance and Risk Committee meetings unless an invitation is extended to the other directors, management and/or employees.

The Remuneration, Nominations and Health & Safety Committee operates under a Charter approved by the Board. The role of the Remuneration, Nominations and Health & Safety Committee is to consider the appointment of any future directors and their suitability to hold that position, the employment of senior executive employees of the Company, and reviewing Health & Safety policies to ensure the Company is providing a safe working environment for all employees and contractors. The Remuneration, Nominations and Health & Safety Committee is also responsible for considering the remuneration to be paid to executive employees and directors.

During the period under review, given the current size of the Board and composition of the sub committees, the Board incorporated all matters of the Remuneration, Nominations and Health & Safety Committee as a separate part of board meetings and accordingly the full board are in practice the members of the committee.

TRADING IN SHARES

The Company has a detailed Financial Markets Trading Policy applying to all directors and employees which can be found at <https://www.metodayinvestors.com/corporate-governance/>. The procedures outlined in this policy must be followed by all Directors and employees to obtain consent to trade in the Group's shares, at all times. Under the policy, trading restrictions (blackout periods) apply:

- two weeks before 31 December until 48 hours after the half-year results are released to NZX;
- two weeks before 30 June 48 hours after the full-year results are released to NZX; and
- 30 days prior to release of an offer document (such as a product disclosure statement or prospectus) for a general public offer of the same class of shares.

Outside the black-out periods specified above, dealing is subject to the notification and consent requirements outlined in the policy.

MAKE TIMELY AND BALANCED DISCLOSURE

The Company has in place procedures designed to ensure compliance with the NZX Listing Rules such that all investors have equal and timely access to material information concerning the Company, including its financial situation, performance, ownership and governance.

Company announcements are factual and presented in a clear and balanced way.

Significant market announcements, including the preliminary announcement of the half year and full year results, and the financial statements for those periods, require review by the Board prior to release.

The Group's Market Disclosure Policy to ensure it complies with its continuous disclosure obligations at all times can be found at <https://www.metodayinvestors.com/corporate-governance/>.

HEALTH AND SAFETY

The Group's Board is responsible for oversight of the Company's health and safety risks. Creating a safe working environment for any employees or contractors is a key focus. Health and safety issues are a separate agenda item on every board meeting where the Board monitors, supports and completes its own due diligence on the health and safety practices.

DIVERSITY POLICY

The Group recognises the wide-ranging benefits that diversity brings to an organisation. Diversity is considered more broadly than gender and includes ethnicity, cultural background, sexual orientation, age and skill. The Company endeavours to incorporate diversity to ensure a balance of skills and perspectives are available to benefit our shareholders, which is reflected in the Company's Diversity Policy, which can be found at <https://www.metodayinvestors.com/corporate-governance/>.

As at 30 June 2023, the gender balance of the Company's directors and officers was as follows:

	2023		2022	
	Female	Male	Female	Male
Directors	1	6	1	6
Officers (excluding directors)	-	-	-	-
Total	1	6	1	6

CORPORATE GOVERNANCE BEST PRACTICE CODE

For the 12 months ended 30 June 2023, the Group has followed the recommendations in the NZX Corporate Governance Code (April 2023 edition) in all material aspects, with the following exceptions:

Reference	Recommendation	Alternative Governance Practice and Reason for the Practice
Recommendation 2.8	A majority of the board should be independent directors.	The Board considers that, although it does not have a majority of independent board members, it has the right balance for the current needs of the Company.
Recommendation 2.9	An issuer should have an independent chair of the board.	Grant Baker, the current chair is not considered to be an independent director as MTL Securities Limited, a company in which he is a director, is a substantial product holder of Me Today. Mr Baker has been appointed as Chair due to the level of expertise that he brings in relation to the Company's current growth focus.
Recommendation 4.4	An issuer should provide non-financial disclosure at least annually, including considering environmental, economic and social sustainability factors and practices. It should explain how operational or non-financial targets are measured. Non-financial reporting should be informative, include forward looking assessments, and align with key strategies and metrics monitored by the board.	Me Today has provided limited reporting on environmental, economic and social sustainability factors to date while it focuses on growing sales. The wellbeing of its customers, employees and other stakeholders is important to Me Today, as is its social responsibility and environmental impact. The Company will implement and report on appropriate non-financial measures in future periods.
Recommendation 8.5	The board should ensure that the notices of annual or special meetings of quoted equity security holders is posted on the issuer's website as soon as possible and at least 20 working days prior to the meeting.	The notice of the Annual Meeting was released on 11 November 2022, being 18 workings days prior to the meeting held on 7 December 2022 to enable completion of director nomination period.



Shareholder & Statutory Information



Statutory Information

FOR THE YEAR ENDED 30 JUNE 2023

Listing

The Company's shares are listed on the NZX Main Board Market operated by NZX Limited ("NZX").

20 largest shareholdings as at 3 August 2023

Name	No. of shares	% of voting Shares
MTL Securities Limited	436,578,473	33.69%
Terrence Wayne Jarvis & Jarvis Burnes Trustee Limited	139,204,546	10.74%
New Zealand Depository Nominee Limited <A/C 1 Cash Account>	73,259,737	5.65%
Forsyth Barr Custodians Limited	72,973,232	5.63%
Custodial Services Limited	62,699,998	4.84%
ASB Nominees Limited	35,000,000	2.70%
Hunter Holdings Limited	35,000,000	2.70%
JPMorgan Chase Bank Na NZ Branch	31,545,455	2.43%
James Patrick Keogh	24,288,971	1.87%
Marvel Fantasy Limited	20,000,000	1.54%
Rhonda Lillian Preston	11,534,091	0.89%
Ilakolako Investments Limited	10,927,273	0.84%
Ashvegas Limited	10,250,000	0.79%
Waitara Trustee Limited	10,153,289	0.78%
Wallflower Limited	8,933,400	0.69%
Foster Capital NZ Limited	8,500,001	0.66%
Antony Vriens	8,159,527	0.63%
Wayne Wright & Chloe Wright	8,009,091	0.62%
WFT Finance Limited	7,659,000	0.59%
Sean Robert Joyce	7,236,046	0.56%

MTL Securities have a total of 684,613,636 as at 3 August 2023, of which 248,035,163 are classified as non-voting and are not quoted on the NZX Main Board.

Distributions of ordinary shares as at 3 August 2023

Size of Holding	Number of Security Holders		Number of Securities	
	Number	%	Number	%
1-999	5	0.61%	281	0.00%
1,000-4,999	68	8.33%	170,310	0.01%
5,000-9,999	55	6.74%	370,748	0.03%
10,000-49,999	239	29.29%	5,683,243	0.44%
50,000-99,999	106	12.99%	6,719,473	0.52%
100,000 or more	343	42.03%	1,282,784,727	99.00%
	816	100.00%	1,295,728,782	100.00%

The above distribution does not include the non-voting ordinary shares held by MTL Securities Limited which are not quoted on the NZX Main Board.

Substantial financial product holders

Pursuant to Section 293 of the Financial Markets Conduct Act 2013, the following are details of substantial financial product holders and their total relevant interests in quoted voting shares as at 30 June 2023.

	Name	No. of Shares	% of shares
	MTL SECURITIES LIMITED	436,578,473	33.69%
	TERRENCE WAYNE JARVIS & JARVIS BURNES TRUSTEE LIMITED	139,204,546	10.74%

Me Today Limited has 1,295,728,782 quoted voting shares on issue as at 30 June 2023. In addition to the 436,578,473 quoted voting shares it holds, MTL Securities holds 248,035,163 non-voting shares as at 30 June 2023. Subject to compliance with the Takeovers Code and applicable exemptions, the non-voting shares may be reclassified as quoted voting shares by written notice to Me Today Limited.

Directors

The names of the directors of Me Today Limited and its subsidiaries holding office during the year are listed below:

Me Today Limited	G Baker H Barrett R Gower M Kerr R Pearson S Sinclair A Vriens
The Good Brand Company Limited	G Baker M Kerr S Sinclair
King Honey Limited	G Baker M Kerr S Sinclair
Me Today NZ Limited Me Today Manuka Honey Limited Today Limited	M Kerr S Sinclair
Me Today USA Inc.	M Kerr S Sinclair
Pure Manuka Limited	M Kerr S Sinclair
King Honey Health Products Limited	M Kerr S Sinclair
Bee Plus Manuka NZ Limited	M Kerr S Sinclair F Henderson
Me Today UK Group Limited	M Kerr S Sinclair L Seaton
Me Today EU Limited	M Kerr S Sinclair T O'Leary C Egan (Outgoing)
Me Today AU Limited	M Kerr S Sinclair F Henderson

Directors' shareholding

G Baker, M Kerr and S Sinclair have a joint relevant interest in 436,578,473 quoted voting shares and 248,035,163 non-voting shares in the Company. H Barrett holds relevant interest in 3,825,285 quoted voting shares in the Company, R Gower holds a relevant interest in 4,537,860 quoted voting shares in the Company. R Pearson holds a relevant interest in 6,117,346 quoted voting shares in the Company. A Vriens holds a relevant interest in 8,159,527 quoted voting shares in the Company.

These relevant interest are stated as at 30 June 2023.

Independent directors

The Board consider H Barrett, R Gower and A Vriens to be independent.

Directors' remuneration

Details of the nature and the amount of remuneration of each director for the year ended 30 June 2023 are:

	Directors' fees NZ\$000	Salary NZ\$000	Consulting fees NZ\$000	Total NZ\$000
Directors' fees and salary				
G Baker (Chairman)	95	-	-	95
H Barrett	75	-	-	75
R Gower	75	-	-	75
M Kerr (CEO)	-	250	-	250
R Pearson	75	-	-	75
S Sinclair	75	-	125	200
A Vriens	75	-	-	75
Total remuneration of directors (excluding GST)	470	250	125	845

No director of a subsidiary receives or retains any remuneration or other benefits from Me Today for acting as such.

Directors' interests

The directors provided the following disclosure of interests in which, due to the nature of their relationship, may be related parties to Me Today Limited.

Grant Baker Baker Consultants Limited MTL Securities Limited Velocity Capital GP Limited	Director / Shareholder Director Director / Shareholder
Hannah Barrett BB Promotions Limited	Shareholder
Roger Gower Roger Gower and Associates Limited	Director / Shareholder
Michael Kerr The Good Brand Company Limited M & N Kerr Holdings Limited MTL Securities Limited	Employee Director / Shareholder Director
Richard Pearson Mei Mei Limited	Director / Shareholder
Stephen Sinclair MTL Securities Limited Velocity Capital GP Limited Stephen Sinclair Consulting Limited	Director Director / Shareholder Director / Shareholder



Indemnification for directors and officers

As permitted by the New Zealand Companies Act 1993, the Group has provided an indemnity for directors and employees of the Company and its subsidiaries for losses from actions undertaken in the course of their duties, unless the liability related to conduct involving lack of good faith or is otherwise not able to be indemnified as a matter of law.

Remuneration of employees

The table below shows the number of employees and former employees (excluding Executive Directors) in the Group receiving remuneration and other benefits in their capacity as employees, the value of which was equal to or exceeded \$100,000 for the 12 months ended 30 June 2023.

Employee remuneration range	2023
	Number of employees
\$100,001 – \$110,000	1
\$110,001 – \$120,000	2
\$120,001 – \$130,000	1
\$140,001 – \$150,000	1
\$150,001 – \$160,000	1
\$160,001 – \$170,000	2
\$190,001 – \$200,000	1
\$200,001 – \$210,000	1

Auditor

BDO Auckland is the auditor for the Group. Audit fees due and payable to the auditor (excluding GST) during the year were \$156,685.

Donations

No donations were paid by the Group during the year.

NZX Waivers

There are no NZX waivers relied upon during the year.

Company directory

Registered Office

Level 1, 25 Broadway
Newmarket
Auckland 1141
New Zealand

Postal Address

PO Box 109047
Newmarket
Auckland 1023

Bankers

BNZ
Deloitte Building
80 Queens Street
Auckland 1010
New Zealand

Lawyers

Chapman Tripp
Level 34, PWC Tower
15 Custom Street West
Auckland 1010
New Zealand

Share Registry

Computershare Investor Services Limited
159 Hurstmere Road
Takapuna
Auckland

Private Bag 92119
Auckland 1142
New Zealand

Auditor

BDO Auckland
4 Graham Street
Auckland
New Zealand

